ApoGlyx develops first-in-class therapies based on aquaporin inhibitors.

Aquaporins are protein channels with broad importance in health and disease, ranging from maintaining the body’s fluid balance to roles in cancer, diabetes, malaria, inflammation, and autoimmunity. The human genome encodes thirteen related aquaporin isoforms, each with a specific expression pattern, and distinct substrate specificity